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Abstract
Background: Enzyme replacement therapy (ERT) with laronidase (recombinant human α-L-iduronidase, Aldurazyme®)
is indicated for non-neurological signs and symptoms of mucopolysaccharidosis type I (MPS I). The approved
laronidase dose regimen is weekly infusions of 0.58mg/kg, however, patients and caregivers may have difficulty
complying with the weekly regimen. We examined clinical outcomes, tolerability, compliance, and satisfaction in
a series of patients who switched to every other week infusions.
Methods: This multinational, retrospective, chart review case series analyzed data from 20 patients who had
undergone ERT with laronidase 0.58mg/kg weekly for more than one year, and who then switched to 1.2mg/kg
every other week.
Results: The majority of patients had attenuated MPS I phenotypes (9 with Hurler-Scheie and 8 with Scheie
syndromes) and 3 patients had severe MPS I (Hurler syndrome). Most patients presented with organomegaly (17/
20), umbilical and/or inguinal hernia (16/20), cardiac abnormalities (17/20), musculoskeletal abnormalities (19/20),
and neurological and/or developmental deficits (15/20). Following laronidase treatment, signs stabilized or
improved. No deterioration or reversal of clinical outcome was noted in any patient who switched from the
weekly dose of 0.58mg.kg to 1.2mg/kg every other week. There were no safety issues during the duration of
every other week dosing. Patient compliance and satisfaction with the dosing regimen were greater with every
other week dosing than weekly dosing.
Conclusions: An alternative dose regimen of 1.2mg/kg laronidase every other week was well tolerated and
clinically similar to the standard dose for patients who were stabilized with weekly 0.58 mg/kg for one year or
more. When an individualized approach to laronidase therapy is necessary, every other week dosing may be an
alternative for patients with difficulty receiving weekly infusions.
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Background
Mucopolysaccharidosis type I (MPS I) is an autosomal
recessive lysosomal storage disorder caused by α-L-
iduronidase (IDUA) deficiency that results in accumu-
lation of the glycosaminoglycans (GAGs) heparan and
dermatan sulfate [1]. Accumulation of IDUA substrates
causes progressive multisystem disease manifestations,
and if left untreated, significant disease burden, disabil-
ity, and premature death. MPS I has variable pheno-
types that range from attenuated to severe classified
according to age of symptom onset, rate of disease pro-
gression, and the extent of neurological involvement
[1, 2]. Patients with Hurler syndrome have the most se-
vere phenotype with onset in infancy and progressive
neurocognitive decline. Patients with attenuated phe-
notypes have either Hurler-Scheie syndrome character-
ized by onset in early childhood with little to moderate
neurocognitive impairment, or Scheie syndrome with
onset in childhood and no neurocognitive involvement.
Clinical presentations include stiff joints, coarse facial
features, hepatomegaly, corneal clouding, hernia, airway-
related and neurologic signs and symptoms, and progres-
sive cardiac disease [2, 3]. Incidence of MPS is estimated
at 1 per 100,000 live births [4].
Hematopoietic stem cell transplantation (HSCT) is
recommended for patients with severe disease before 2
years of age in order to protect the nervous system and
prolong survival. Enzyme replacement therapy with lar-
onidase (recombinant human α-L-iduronidase, Aldura-
zyme®) targets non-neurological manifestations as the
recombinant enzyme does not cross the blood-brain
barrier. Laronidase reduces biochemical measures of
MPS I (urinary GAG excretion) and organ GAG accu-
mulation, and improves functional capacity (e.g., pul-
monary function, distance walked, and mobility) [5–7].
The current approved laronidase dose regimen is 0.58
mg/kg (100 U/kg) weekly, administered intravenously
for life. Patients and caregivers of patients with MPS I
frequently relay to physicians the difficulties of comply-
ing with weekly infusion regimen [8]. As a result, physi-
cians may try other dosing regimens for patients in
order to improve compliance with therapy. A 26-week
dose optimization trial assessed alternative laronidase
dose regimens including 1.2 mg/kg dose every other
week [9]. There were no significant differences in the re-
duction of urinary GAG excretion or liver volumes in
patients on the weekly or every other week regimens.
While incidence of drug-related adverse events was low-
est for patients in the weekly regimen, the every other
week dose regimen was well tolerated. Therefore, the 1.2
mg/kg every other week regimen may be an alternative
for patients with difficulty receiving weekly infusions.
In the absence of long-term studies to assess an every
other week laronidase dosing regimen, we examined
clinical outcomes, compliance and satisfaction with the
dosing regimens in a series of patients who switched to
1.2 mg/kg every other week infusions because of diffi-
culty complying with a weekly infusion schedule.
Methods
This multinational, retrospective, chart review case series
was conducted at the authors’ institutions. All patients
with MPS I were diagnosed by biochemical determination
of enzyme activity and/or genetic analysis. No selection
was made among eligible patients. All patients who had
undergone ERT with the recommended laronidase dose of
0.58 mg/kg weekly for more than one year, and who then
switched to 1.2 mg/kg every other week were eligible for
inclusion. Reasons for changing dosing regimens were re-
corded in patient records. All patients provided informed
consent, which included consent for subsequent data ex-
traction from chart review as needed.
Data collection
Treating physicians abstracted data on the signs and
symptoms of patients with MPS I. Data were collected at
diagnosis (Time point 1, T1), at a time point prior to ini-
tiating every other week dosing (Time point 2, T2), and
following at least 1 year of every 2 week dosing (Time
point 3, T3). Data from medical histories and neurological,
cardiovascular, pulmonary, gastroenterology, musculoskel-
etal, and corneal clouding examinations were abstracted
and summarized including: duration of ERT, reasons for
regimen change, general appearance observed during
physical examination, GAG levels and laboratory values,
auditory signs, presence of corneal clouding and hernia,
results of pulmonary function tests (PFT), liver and spleen
size determined by palpation and/or imaging studies and
severity based on size, cardiac disease description/severity
determined from echocardiogram, joint and skeletal dis-
ease observed during physical examination and/or radio-
graphic imaging, presence/severity of dysostosis multiplex,
and neurologic and motor development delays assessed
during physical examination.
Data on patient compliance with therapy (number of
doses received/number of expected doses x 100) and as-
sessment by patients/caregivers of their satisfaction with
the change in dosing regimen were summarized.
Incidence of infusion associated reactions (IARs) and any
safety issues during every other week dosing were reported.
Results and discussion
Twenty (20) patients were included in the case analysis.
Three patients were diagnosed with severe (Hurler syn-
drome) and 17 had attenuated (9 with Hurler-Scheie and
8 with Scheie syndromes) disease. Individual treatment
profiles and summary statistics are shown in Table 1.
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Patient age at diagnosis was lower in patients with
Hurler syndrome (median 1.67 years) and greater than
5 years of age for patients with attenuated disease (me-
dians of 5.0 years for patients with Hurler-Scheie, and
11.0 years for patients with Scheie syndrome). The age
of patients at the start of weekly laronidase treatment
varied by phenotype, with a median of 2.08 years for
patients with Hurler syndrome and 15.13 years for pa-
tients with Scheie syndrome. The gap between diagno-
sis and onset of treatment was longest for patients
with attenuated disease. However, the time between
diagnosis and treatment for some patients reflected
that treatment was not commercially available at the
time of diagnosis.
These data are consistent with the pattern of symp-
tom onset and diagnosis times typically observed across
MPS I phenotypes [10, 11], where patients with more
severe disease have earlier onset and are diagnosed at a
younger age than patients with attenuated phenotypes.
Importantly, the long-term clinical benefits achieved
with ERT appear to be largely dependent on early diag-
nosis and treatment [12–15]. A case study demon-
strated the benefits of early treatment in two siblings
with MPS I, where the younger sibling developed few
Table 1 Treatment Profiles for all Patients
Laronidase Regimen
0.58 mg/kg Weekly 1.2 mg/kg Every other week
Patient ID MPS I Phenotype Age at Dx Age at Start Duration Age at Start Duration
years
1 H 2.42 4.25 1.66 6.00 7.75
2 H 1.17 1.83 4.33 6.17 6.33
3 H 1.67 2.08 1.83 3.92 1.00
Mean (SD) 1.75 (0.63) 2.72 (1.33) 2.61 (1.49) 5.36 (1.25) 5.03 (3.56)
Median
(Range)
1.67 2.08 1.83 6.00 6.33
(1.17-2.42) (1.83-4.25) (1.66-4.33) (3.92-6.17) (1.00-7.75)
4 H-S 1.92 2.42 1.58 4.00 2.00
5 H-S 2.50 5.08 1.50 9.92 2.08
6 H-S 5.17 8.33 1.50 13.00 2.92
7 H-S 2.00 21.00 4.00 25.00 9.00
8 H-S 7.25 9.42 2.70 12.33 1.10
9 H-S 5.00 6.75 1.17 7.91 2.00
10 H-S 15.92 17.17 1.58 18.75 6.75
11 H-S 3.25 4.75 1.33 6.08 5.42
12 H-S 7.50 12.08 1.25 13.33 6.42
Mean (SD) 5.61(4.4) 9.67 (6.11) 1.85 (0.92) 12.26 (6.49) 4.19 (2.77)
Median
(Range)
5.0 8.33 1.5 12.33 2.92
(1.92–15.92) (2.42–21.0) (1.33–4.0) (4.0–25.0) (1.1–9.0)
13 S 5.00 6.00 2.00 8.00 6.00
14 S 6.00 6.33 3.42 9.75 2.75
15 S 7.00 10.00 3.00 13.00 6.00
16 S 12.00 12.25 3.42 15.67 2.75
17 S 15.92 20.08 1.59 21.67 6.33
18 S 10.00 19.00 5.00 24.00 3.67
19 S 14.00 18.00 5.00 23.00 3.67
20 S 20.00 21.00 4.00 25.00 5.00
Mean (SD) 11.24 (5.25) 14.08 (6.20) 3.43 (1.25) 17.51 (6.76) 4.52 (1.49)
Median
(Range)
11.00 15.13 3.42 18.67 4.34
(5.0–20.0) (6.0–21.0) (1.59–5.00) (8.0–25.0) (2.75–6.33)
Data in italic are the mean and median of the 3 different patient groups
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signs and symptoms after starting treatment at 5
months of age compared to an older sibling who began
laronidase at 5 years of age and had persistent cardiac
and musculoskeletal signs and symptoms [14]. Another
case series reported similar findings in three siblings
treated with laronidase, where the eldest child who
began treatment at age 6 after onset of significant signs
and symptoms still had significant clinical features of
the disease, while siblings who started therapy at earlier
ages (2.5 years and 4 months of age) had milder disease
courses [13]. A large multinational case series of 20 pa-
tients with attenuated MPS I from 9 sibships where
younger siblings received ERT prior to the development
of significant signs and symptoms reported that cardiac,
musculoskeletal, and cognitive signs and symptoms,
when absent or mild in younger siblings at ERT initi-
ation, generally did not develop or progress [15]. These
findings suggest that early initiation of ERT prior to the
onset of signs and symptoms can slow or prevent the
development of severe clinical manifestations. Clinical
features such as cardiac valve disease, corneal clouding,
and skeletal changes may not respond as well to ERT
since irreversible pathology is already present by the
time symptoms appear.
The duration of weekly laronidase therapy was ≥ 1 year
for all patients and ranged from 1.3 to 5 years (median
1.92). The duration of 1.2 mg/kg every other week
ranged from 1 to 9 years (median 3.67). Treatment dura-
tions by phenotype are shown in Table 1 and were simi-
lar across the groups.
Clinical presentation at diagnosis
The majority of patients (18/19) presented with coarse
facial features and corneal clouding at the time of diag-
nosis (T1). Hearing loss was reported in 8/18 patients.
Most patients had organomegaly (13/19), hernia (umbil-
ical and/or inguinal) (14/19), cardiac abnormalities (15/
19), musculoskeletal abnormalities (19/19), and neuro-
logical and/or developmental deficits (15/20). As would
be expected based on the phenotypic categories, signs
were most severe in patients with Hurler syndrome and
the least severe in patients with Scheie syndrome. There
was considerable variability in the presentations of the 9
patients with Hurler-Scheie phenotype, which is not sur-
prising given the broad age range at which the patients
were first treated with laronidase, as shown in Table 1
(range 2.4–21 years).
Clinical outcomes post-laronidase
Patients with coarse facial features, hearing loss, and
corneal clouding at the time of diagnosis had persistence
of these signs at T2 and T3, although coarse facial fea-
tures were noted to improve in some patients. In gen-
eral, signs stabilized (i.e., they did not progress or never
developed), or improved with laronidase treatment and
switching to dosing every other week did not reverse the
clinical outcome observed following weekly dosing. Im-
portantly, no deterioration was noted in any patient who
switched from the weekly dose of 0.58 mg/kg to every
other week dosing with 1.2 mg/kg. Since discontinuation
of weekly laronidase can be associated with rapid deteri-
oration in clinical presentation [16], these results sup-
port that administering a double dose of laronidase
every other week maintains adequate enzyme blood
levels as has been previously suggested by pharmacody-
namic evaluation of every other week dosing regimens
in patients with MPS I [9]. No patient reverted to weekly
laronidase infusions. While the assessment of changes in
severity of clinical signs was limited by the retrospective
nature of the study and the lack of a formal scoring sys-
tem, it is important to note that most of the patients
were followed by the same clinical group for many years,
and therefore bias in assessing outcomes for the individ-
ual patients was minimized. In particular, for severity of
musculoskeletal and cardiac disease, imaging results be-
fore and after initiating laronidase treatment were
assessed by the same individual. Therefore, while a stan-
dardized scoring system was not used for determining
severity, physicians were better able to assess disease
progression or lack thereof for a given patient.
Urinary GAG levels decreased following initiation of
the standard laronidase regimen in 15/17 patients, and
levels were similar with every 2 week dosing. Levels were
within normal ranges for 14/17 patients at T3. Urinary
GAG levels at T1, T2, and T3 expressed as the fold in-
crease above the reference or within normal limits (N)
are shown in Table 2.
Pulmonary function test data were limited for these
patients. Three patients had data at both the T2 and T3
assessments. Patient 7 had Hurler-Scheie syndrome and
had FVC and FEV1 values at 33 % and 27 % of predicted
normal values, respectively, at T2. These values were es-
sentially unchanged at the T3 assessment (38 % and 30 %,
respectively). Two patients with Scheie syndrome had T2
values (82 % and 85 % for FVC, and 94 % and 81 % for
FEV1) that were unchanged or slightly improved at T3.
Organomegaly improved, and cardiac, musculoskeletal,
and neurodevelopmental signs stabilized or progressed
consistent with patterns described in clinical trials and the
natural history of the disease [5, 17, 18]. The following
sections describe these signs for the individual patients.
Organomegaly
In general, organomegaly improved at T2 compared to
T1 and remained stable at T3, and was absent at T3 in
18/20 patients. In patients with Hurler syndrome,
signs improved in 2 patients (Patients 1 and 2) and
organomegaly did not develop in the remaining patient
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(Patient 3). Organomegaly data are summarized in
Fig. 1. These results indicate that, similar to the urin-
ary GAG data, most of the patients had already experi-
enced the clinical benefits of undergoing ERT, and that
switching to the alternative dose regimen did not com-
promise the positive outcomes.
Cardiac signs
Laronidase is believed to stabilize but not improve cardiac
disease when pathological changes are already present at
the start of treatment, and early initiation of ERT may
help prevent the onset of disease features [13, 19]. As pre-
viously reported for patients on long-term laronidase
treatment [19], there was no progression to heart failure
or cor pulmonale for the patients in this case series, but
valve disease did progress in some patients. Patients in this
series had a wide range of ages at the time of laronidase
initiation as shown in Table 1, with earliest onset of treat-
ment for patients with Hurler syndrome. Patients with
Hurler and Hurler-Scheie syndrome had cardiac signs at
diagnosis ranging from mitral and/or aortic valve thicken-
ing, mitral insufficiency, mitral stenosis, mitral/and or tri-
cuspid valve regurgitation, and cardiomyopathy.
Cardiac signs were mild or absent at all assessments
in patients with Scheie syndrome, with the exception of
moderate mitral regurgitation in Patient 15 which was
stable at T2 and T3. Figure 2 shows the severity of
valve disease over time for patients with severity data at
all three time points stratified by phenotype, [Hurler
Syndrome (A), Hurler-Scheie Syndrome (B) and Scheie
Syndrome (C)]. Signs progressed in 4 patients following
laronidase treatment (T1 to T2 and/or T3), and were
stable in 8 patients. Although improvements were seen
in 5 patients, it is generally accepted that valve disease
does not benefit from ERT, and perceived improve-
ments may be attributable to the subjective nature of
the grading system used in this study and the fact that
echocardiograms may have been assessed by different
physicians during follow up. Ten of 20 patients had no
cardiomyopathy at T1 and cardiomyopathy did not de-
velop following either weekly or every other week laro-
nidase treatment. Five patients had cardiomyopathy at
Table 2 Measurements of urinary GAGs under weekly and
biweekly dose regimens
Fold increase (mg/GAG/mmol creatinine)
above reference range;
N = within normal limits
Patient Phenotype T1 T2 T3
1 H 5 N N
2 H 9 N N
3 H 19 2.3 3.8
5 HS 16 N N
6 HS 43 N N
7 HS NA 2.9 N
8 HS 4.4 N N
9 HS 9 N N
10 HS 23 N N
11 HS 9.6 N N
12 HS 4.8 1.2 N
14 S 5 1.2 2.9
16 S 7.9 2.4 1.8
17 S 148 1.1 N
18 S 3.7 N N
19 S 1.7 2.1 1.2
20 S 2.7 N 1.2
T1 T2 T3
Organomegaly
3
4
13
17
19
20
1
2
14
15
16
18
5
9
10
11
12
6
8
Present
Improved
Absent
Absent at all times
Improved at T3
No change
Patient Id
Fig. 1 Changes in organomegaly. Organomegaly at time of diagnosis (T1), initiation of laronidase every other week dosing following weekly laronidase
dosing regimen (T2), and follow-up assessment (T3). In 6 patients (aqua) there was no organomegaly at any time point. In 6 patients (red), organome-
galy present at T1 was absent at T2 and T3. In six of the remaining patients (blue, and green), organomegaly was improved/absent at T3 compared to
T1, and in one patient (yellow) organomegaly was not changed at T2 or T3 compared to T1
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T1 that remained, and 5 patients had cardiomyopathy
at T1 but not at the post-treatment assessments.
In summary, cardiac disease type and severity were
similar for the weekly and every other week dosing regi-
men. Despite progression of valve disease in some pa-
tients, most patients remained in the mild range for
valve disease a T3.
Musculoskeletal signs
Improved mobility, endurance, and range of motion
are noted in patients following laronidase treatment
[7, 12, 17, 19]. However, joint disease and skeletal dis-
ease do not generally improve with laronidase treatment if
pathological changes are already established [12]. There
were sparse data to be able to compare endurance and
mobility (e.g., using 6 min walk tests, 6MWT) at diagnosis
and at the T2 and T3 assessments. Five patients (#14, 16,
18, 19 and 20) with Scheie syndrome had 6MWT data at
all assessments (n = 3) or only the T2 and T3 (n = 2). In all
cases, distances walked at the T3 assessment were similar
to or greater than distances walked at the T1 and/or T2
assessments, indicating no deterioration in mobility or en-
durance after commencing every other week dosing with
1.2 mg/kg laronidase.
In general, most patients had dysostosis multiplex
and joint contractures of the upper and lower extrem-
ities at diagnosis, and these signs persisted at the T2
and T3 assessments. Eleven patients with these signs
had no severity data (Patients 4, 5, 6, 8, 9, 10, 11, 13,
15, and 17). For patients with information on the sever-
ity of musculoskeletal signs, most had similar impair-
ment at all three time points, which ranged from mild
to severe, and was most severe in patients with Hurler
syndrome. Among patients with Hurler-Scheie syn-
drome, musculoskeletal signs ranged from mild to se-
vere and were similar at all assessments.
Patients with Scheie syndrome had milder musculo-
skeletal impairment than patients with Hurler-Scheie
syndrome, and the severity of signs was similar at all as-
sessments, or was similar at T2 and T3 if signs pro-
gressed from T1.
Neurological and developmental
The severity of neurological or developmental delays at
T2 and T3, in general, were similar to the presentations
at diagnosis. Among patients with Hurler syndrome,
Patient 1 had cognitive delays at all assessments (no data
on motor skills). Patient 2 had mild to moderate delays in
fine and gross motor skills and delayed cognitive function
at all time points, and Patient 3 had severely delayed neu-
rocognitive functions and fine and gross motor skills at
T1, with some improvement noted at T3.
As with cardiac and musculoskeletal signs, there was
variability in cognitive presentation among patients with
Hurler-Scheie syndrome. For patients 4, 5, 9, 10, 11, 6, 7,
8, 9, and 12, sign presentation and severity were similar
at all assessments and ranged from normal neurological
and developmental assessments to delayed cognitive func-
tion with mild to moderate motor development delays.
Most patients with Scheie syndrome had normal cog-
nitive development (Patients 13, 15, and 17, 18, and 19)
and normal to mildly impaired fine and gross motor
skills (Patients 13, 14, 15, 16, 17, 18, 19, and 20) with
similar assessments at all time points. Patients 14 and 16
had moderate range of intellect and no sign of organicity
at T1 (determined by medical and psychological assess-
ments), while intellect was subnormal with signs of orga-
nicity at T3.
T1 T2 T3
Hurler Syndrome 1
2
3
Moderate/Severe
Mild/Moderate
Mild
Absent
T1 T2 T3
Hurler-Scheie Syndrome 4
5
6
10
Severe
Mild/Moderate
Mild
Absent
T1 T2 T3
11
12Mild/Moderate
Mild
Absent
T1 T2 T3
Scheie Syndrome                                13
14
15
16
Moderate
Mild
Absent
T1 T2 T3
17
18
19
20
Mild
Absent
Patient Id
Fig. 2 Changes in cardiac valve disease over time for patients with
severe (Hurler, panel A) or attenuated MPS I (Hurler-Scheie, panel B
and Scheie, panel C). Cardiac symptoms improved in Patients 1, 11,
14 and 20 at T2 or T3. Signs at T1 remained stable at T2 and T3 in
Patients 4, 6, 10, 12, 15, 16, 17, and 18. Signs progressed in Patients
2, 3, 5, 13 and 17. Signs at T3 were absent or mild in Patients 1, 4,
10-14, and 16-20
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Patient compliance and satisfaction with the treatment
regimen
The reasons for regimen changes varied for patients,
but included convenience issues (e.g., the commute to
the center for weekly infusions was too long) and qual-
ity of life issues (fewer school days missed; fewer care-
giver work days missed). All patients responded that
they were satisfied, very satisfied, or very pleased with
the regimen, that it was a better regimen than the every
week schedule, that they were much happier with the
regimen, or that QoL improved/significantly improved
with no worsening of signs.
Compliance data with the weekly or every other week
dosing regimen were available for 10 patients (Patients
1, 5, 6, 8, 9, 10, 11 14, 16, and 17), and demonstrated
that compliance increased (median increase of 13 %)
when patients changed to every other week dosing. The
median (range) compliance during weekly dosing was 80
% (67-88 %) and improved to 93 % (79-100 %) during
every other week dosing.
Tolerability
Physicians reported that there were no safety issues
and/or no IARs during the duration of the every other
week dosing for 19/20 patients. Data were not available
for Patient 15.
Conclusions
An alternative dose regimen of 1.2 mg/kg laronidase in-
fusions every other week in MPS I patients was well tol-
erated and clinically similar to the standard dose for
patients who were stabilized with 0.58 mg/kg every week
for one year or more. Every other week dosing also re-
sulted in greater patient compliance and satisfaction. An
individualized approach to laronidase dosing may be an ef-
ficient method for improving the treatment condition and
therapy outcome of patients with MPS I, however, more
detailed prospective studies with larger numbers of pa-
tients would be useful to confirm that laronidase 1.2 mg/
kg/dose every 2 weeks may be used safely in the long term.
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